Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7050395 | 0.82 | CYP2D6 (0.67) | CYP2D6KMT2APTGS2CYP3A4MAPK1 | |
| SCHEMBL7052728 | 0.80 | GAA (0.42) | CYP2D6FFAR2AKR1C3AKR1C2KCNA5 | |
| SCHEMBL28132724 | 0.76 | CYP2D6 (0.46) | CYP2D6FFAR2NAPRTSLC6A2SLC6A4 | |
| SCHEMBL1690400 | 0.75 | AKR1C3 (0.56) | AKR1C3AKR1C2NAPRTGAASLC6A2 | |
| SCHEMBL10368591 | 0.75 | NAPRT (0.44) | CYP2D6AKR1C3AKR1C2NAPRTSLC6A2 | |
| SCHEMBL14537418 | 0.75 | AKR1C3 (0.56) | AKR1C3AKR1C2NAPRTGAASLC6A2 | |
| SCHEMBL1574188 | 0.75 | NAPRT (0.44) | CYP2D6AKR1C3AKR1C2NAPRTSLC6A2 | |
| Hydrochloric Acid SCHEMBL8937692 | 0.74 | AKR1C3 (0.54) | AKR1C3AKR1C2NAPRTCYP19A1PTGS2 | |
| SCHEMBL7047206 | 0.73 | LMNA (0.41) | AKR1C3AKR1C2NAPRTGAACYP19A1 | |
| SCHEMBL4128071 | 0.72 | PRCP (0.42) | AKR1C3AKR1C2NAPRTGAACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| US-6265609-B1 | INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY; IN DRUGS TO TREAT GLUTAMATE ABNORMALITIES; COMPULSIVE DISORDERS AND PROSTATE DISEASES, TO EFFECT NEURONAL ACTIVITIES | GUILFORD PHARMACEUTICALS INC. | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | CYP2D6 3489/4885FFAR2 3810/4885AKR1C3 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.